Kevin S. Douglas, Laura S. Guy, Stephen D. Hart:Psychosis as a risk factor for violence to others: A meta-analysis. In: Psychological Bulletin. Band135, Nr.5, 2009, ISSN1939-1455, S.679–706, doi:10.1037/a0016311 (apa.org[abgerufen am 23.Dezember 2018]).
Josef Bäuml: Psychosen aus dem schizophrenen Formenkreis: Ratgeber für Patienten und Angehörige, Leitfaden für professionelle Helfer, Einführung für interessierte Laien. 2., aktualisierte und erweiterte Auflage. Springer, Heidelberg 2008, ISBN 978-3-540-43646-1, S. 39 f. (GoogleBooks) und S. 9.
Dorothea von Haebler, Stavros Mentzos, Günter Lempa (Hrsg.):Psychosenpsychotherapie im Dialog. Zur Gründung des DDPP (=Forum der psychoanalytischen Psychosentherapie. Band26). Vandenhoeck & Ruprecht, Göttingen 2011, ISBN 978-3-525-45127-4 (Inhaltsverzeichnis).
Dorothea von Haebler, Stavros Mentzos, Günter Lempa (Hrsg.):Psychosenpsychotherapie im Dialog. Zur Gründung des DDPP (=Forum der psychoanalytischen Psychosentherapie. Band26). Vandenhoeck & Ruprecht, Göttingen 2011, ISBN 978-3-525-45127-4 (Inhaltsverzeichnis).
S. Klingberg, K. Hesse: Differenzialindikation für die Psychotherapie bei Psychosen. In: Der Nervenarzt. Band 89, 2018, S.276–282, doi:10.1007/s00115-017-0474-0 (Review).
H. Müller, S. Laier, A. Bechdolf: Evidence-based psychotherapy for the prevention and treatment of first-episode psychosis. In: European archives of psychiatry and clinical neuroscience. Band 264, Supplement 1, November 2014, S.S17–S25. doi:10.1007/s00406-014-0538-0. PMID 25261211 (Review), PDF.
M. Bürgy: The concept of psychosis: historical and phenomenological aspects. In: Schizophrenia bulletin. Band 34, Nummer 6, November 2008, S.1200–1210, doi:10.1093/schbul/sbm136. PMID 18174608, PMC2632489(freier Volltext).
Werner Janzarik:Der Psychose-Begriff und die Qualität des Psychotischen. In: Der Nervenarzt. Band74, Nr.1, 1.Januar 2003, S.3–11, doi:10.1007/s00115-002-1348-6.
A. S. Khashan, K. M. Abel, R. McNamee, M. G. Pedersen, R. T. Webb, P. N. Baker, L. C. Kenny, P. B. Mortensen: Higher risk of offspring schizophrenia following antenatal maternal exposure to severe adverse life events. In: Archives of general psychiatry. Band 65, Nummer 2, Februar 2008, S.146–152, doi:10.1001/archgenpsychiatry.2007.20. PMID 18250252.
J. E. Lisman, J. T. Coyle, R. W. Green, D. C. Javitt, F. M. Benes, S. Heckers, A. A. Grace: Circuit-based framework for understanding neurotransmitter and risk gene interactions in schizophrenia. In: Trends in neurosciences. Band 31, Nummer 5, Mai 2008, S.234–242. doi:10.1016/j.tins.2008.02.005. PMID 18395805, PMC2680493(freier Volltext) (Review).
Kristina M. Gicas; Puneet K. Parmar; Giulia F. Fabiano; Farzaneh Mashhadi:Substance-induced psychosis and cognitive functioning: A systematic review. In: Psychiatry Res. 308. Jahrgang, Februar 2022, S.114361, doi:10.1016/j.psychres.2021.114361, PMID 34979380 (englisch).
Annika Clamor, Inga Frantz, Tania M. Lincoln:Psychotische Störungen und Schizophrenie. In: Klinische Psychologie & Psychotherapie. Springer Berlin Heidelberg, Berlin, Heidelberg 2020, ISBN 978-3-662-61813-4, S.947–1003, doi:10.1007/978-3-662-61814-1_44 (springer.com[abgerufen am 28.Juni 2024]).
Michael Soyka:Psychopathological characteristics in alcohol hallucinosis and paranoid schizophrenia. In: Acta Psychiatrica Scandinavica. Band81, Nr.3, März 1990, S.255–9, doi:10.1111/j.1600-0447.1990.tb06491.x, PMID 2343749.
R. Thomasius, E. Gouzoulis-Mayfrank u.a.: AWMF-Behandlungsleitlinie: Psychische und Verhaltensstörungen durch Kokain, Amphetamine, Ecstasy und Halluzinogene. In: Fortschritte der Neurologie – Psychiatrie. 72, 2004, S.679, doi:10.1055/s-2004-818531.
M. C. White, J. J. Silverman, J. W. Harbison:Psychosis associated with clonazepam therapy for blepharospasm. In: The Journal of Nervous and Mental Disease. Band170, Nr.2, Februar 1982, S.117–9, doi:10.1097/00005053-198202000-00010, PMID 7057171.
R. J. Hallberg, K. Lessler, F. J. Kane:Korsakoff-Like Psychosis Associated With Benzodiazepine Overdosage. In: The American Journal of Psychiatry. Band121, Nr.2, August 1964, S.188–9, doi:10.1176/ajp.121.2.188, PMID 14194223 (psychiatryonline.org).
J. M. Cerimele, A. P. Stern, D. Jutras-Aswad:Psychosis following excessive ingestion of energy drinks in a patient with schizophrenia. In: The American Journal of Psychiatry. Band167, Nr.3, März 2010, S.353, doi:10.1176/appi.ajp.2009.09101456, PMID 20194494.
S. Glasner-Edwards, L. J. Mooney: Methamphetamine psychosis: epidemiology and management. In: CNS drugs. Band 28, Nummer 12, Dezember 2014, S.1115–1126, doi:10.1007/s40263-014-0209-8. PMID 25373627, PMC5027896(freier Volltext) (Review).
F. Rugani, S. Bacciardi, L. Rovai, M. Pacini, A. G. Maremmani, J. Deltito, L. Dell'osso, I. Maremmani: Symptomatological features of patients with and without Ecstasy use during their first psychotic episode. In: International journal of environmental research and public health. Band 9, Nummer 7, 07 2012, S.2283–2292, doi:10.3390/ijerph9072283. PMID 22851941, PMC3407902(freier Volltext).
A. M. Tomé, A. Filipe: Quinolones: review of psychiatric and neurological adverse reactions. In: Drug safety. Band 34, Nummer 6, Juni 2011, S.465–488, doi:10.2165/11587280-000000000-00000, PMID 21585220 (Review), PDF.
K. Michalak, A. Sobolewska-Włodarczyk, M. Włodarczyk, J. Sobolewska, P. Woźniak, B. Sobolewski: Treatment of the Fluoroquinolone-Associated Disability: The Pathobiochemical Implications. In: Oxidative medicine and cellular longevity. Band 2017, S.8023935, doi:10.1155/2017/8023935. PMID 29147464, PMC5632915(freier Volltext) (Review).
M. E. John, C. Thomas-Rozea, D. Hahn: Bath Salts Abuse Leading to New-Onset Psychosis and Potential for Violence. In: Clinical schizophrenia & related psychoses. Band 11, Nummer 2, Sommer 2017, S.120–124, doi:10.3371/CSRP.JORO.061314. PMID 24951715 (Review).
S. H. Gage, M. Hickman, S. Zammit: Association Between Cannabis and Psychosis: Epidemiologic Evidence. In: Biological psychiatry. Band 79, Nummer 7, April 2016, S.549–556, doi:10.1016/j.biopsych.2015.08.001, PMID 26386480 (Review) (freier Volltext).
Matthew D. Albaugh, Jonatan Ottino-Gonzalez u.a.: Association of Cannabis Use During Adolescence With Neurodevelopment. In: JAMA Psychiatry. 78, 2021, S.1031, doi:10.1001/jamapsychiatry.2021.1258.
S. D. Lichenstein, N. Manco u.a.: Systematic review of structural and functional neuroimaging studies of cannabis use in adolescence and emerging adulthood: evidence from 90 studies and 9441 participants. In: Neuropsychopharmacology. Band 47, Nummer 5, 04 2022, S.1000–1028, doi:10.1038/s41386-021-01226-9, PMID 34839363, PMC8938408(freier Volltext).
L. Prieto-Arenas, I. Díaz, M. C. Arenas: Gender Differences in Dual Diagnoses Associated with Cannabis Use: A Review. In: Brain sciences. Band 12, Nummer 3, März 2022, doi:10.3390/brainsci12030388, PMID 35326345, PMC8946108(freier Volltext) (Review).
Hendrik Müller, Andreas Bechdolf:Früherkennung und Frühbehandlung von Menschen mit erhöhtem Psychoserisiko. In: Handbuch Klinische Psychologie. Springer Berlin Heidelberg, Berlin, Heidelberg 2020, ISBN 978-3-662-45995-9, S.1–25, doi:10.1007/978-3-662-45995-9_26-1 (springer.com[abgerufen am 30.Juni 2024]).
G. Remington, G. Foussias, G. Fervaha, O. Agid, H. Takeuchi, J. Lee, M. Hahn: Treating Negative Symptoms in Schizophrenia: an Update. In: Current treatment options in psychiatry. Band 3, 2016, S.133–150, doi:10.1007/s40501-016-0075-8. PMID 27376016, PMC4908169(freier Volltext) (Review).
Jan Conradi, Matthias Jäger, Stefan Kaiser:Update: Negativsymptome – Psychopathologie, Epidemiologie, Pathophysiologie und Behandlungsoptionen. Zürich Open Repository and Archive. 2013, doi:10.5167/uzh-91302 (uzh.ch[PDF]).
F. Bourque, E. van der Ven, A. Malla: A meta-analysis of the risk for psychotic disorders among first- and second-generation immigrants. In: Psychological medicine. Band 41, Nummer 5, Mai 2011, S.897–910, doi:10.1017/S0033291710001406. PMID 20663257 (Review), PDF.
U. Heilbronner, M. Samara, S. Leucht, P. Falkai, T. G. Schulze: The Longitudinal Course of Schizophrenia Across the Lifespan: Clinical, Cognitive, and Neurobiological Aspects. In: Harvard review of psychiatry. Band 24, Nummer 2, 2016 Mar-Apr, S.118–128, doi:10.1097/HRP.0000000000000092. PMID 26954596, PMC5079232(freier Volltext) (Review).
A. L. Gillespie, R. Samanaite, J. Mill, A. Egerton, J. H. MacCabe: Is treatment-resistant schizophrenia categorically distinct from treatment-responsive schizophrenia? a systematic review. In: BMC psychiatry. Band 17, Nummer 1, 01 2017, S.12, doi:10.1186/s12888-016-1177-y. PMID 28086761, PMC5237235(freier Volltext) (Review).
Leweke et al.: Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. In: Translational Psychiatry. 2012, doi:10.1038/tp.2012.15.
Boggs et al.: The effects of cannabidiol (CBD) on cognition and symptoms in outpatients with chronic schizophrenia a randomized placebo controlled trial. In: Psychopharmacology (Berl). 2018, doi:10.1007/s00213-018-4885-9.
McGuire et al.: Cannabidiol (CBD) as an Adjunctive Therapy in Schizophrenia: A Multicenter Randomized Controlled Trial. In: American Journal of Psychiatry. Band 175, Nummer 3, 2018, doi:10.1176/appi.ajp.2017.17030325.
Bhattacharyya et al.: Effect of Cannabidiol on Medial Temporal, Midbrain, and Striatal Dysfunction in People at Clinical High Risk of Psychosis. In: JAMA Psychiatry, 75(11), 2018. doi:10.1001/jamapsychiatry.2018.2309.
Di Forti et al.: The contribution of cannabis use to variation in the incidence of psychotic disorder across Europe. In: The Lancet Psychiatry, 2019. doi:10.1016/S2215-0366(19)30048-3.
de Almeida, Devi: Diversity of molecular targets and signaling pathways for CBD. In: Pharmacol Res Perspect, 2020. doi:10.1002/prp2.682.
van Boxel et al.: The impact of cannabidiol treatment on resting-state functional connectivity, prefrontal metabolite levels and reward processing in recent-onset patients with a psychotic disorder. In: J Psychiatr Res, 2023. doi:10.1016/j.jpsychires.2023.05.019.
Oliver, McGuire et al.: Acceptability of cannabidiol as a treatment for people at clinical high risk for psychosis. 2026. doi:10.64898/2026.03.05.26347694
B. Adams, T. Sanders: Experiences of psychosis in borderline personality disorder: a qualitative analysis. In: Journal of mental health. Band 20, Nummer 4, August 2011, S.381–391, doi:10.3109/09638237.2011.577846. PMID 21770785 (Review).
S. Barnow, E. A. Arens, S. Sieswerda, R. Dinu-Biringer, C. Spitzer, S. Lang: Borderline personality disorder and psychosis: a review. In: Current psychiatry reports. Band 12, Nummer 3, Juni 2010, S.186–195, doi:10.1007/s11920-010-0107-9. PMID 20425279 (Review), PDF.
K. Schroeder, H. L. Fisher, I. Schäfer: Psychotic symptoms in patients with borderline personality disorder: prevalence and clinical management. In: Current opinion in psychiatry. Band 26, Nummer 1, Januar 2013, S.113–119, doi:10.1097/YCO.0b013e32835a2ae7. PMID 23168909 (Review).
Jeffrey A Lieberman, Michael B First:Review Article: Psychotic Disorders. In: The New England Journal of Medicine. Band379, 2018, S.270–280, doi:10.1056/NEJMra1801490.
Epidemiology of suicide attempts among persons with psychotic disorder in the general population. In: Schizophrenia Research. Band124, Nr.1–3, 1.Dezember 2010, ISSN0920-9964, S.22–28, doi:10.1016/j.schres.2010.09.009 (sciencedirect.com[abgerufen am 23.Dezember 2018]).
M. Lambert, P. Conus, D. I. Lubman, D. Wade, H. Yuen:The impact of substance use disorders on clinical outcome in 643 patients with first-episode psychosis. In: Acta Psychiatrica Scandinavica. Band112, Nr.2, 2005, ISSN1600-0447, S.141–148, doi:10.1111/j.1600-0447.2005.00554.x (wiley.com[abgerufen am 23.Dezember 2018]).
D. P. Folsom, W. Hawthorne, L. Lindamer und andere:Prevalence and risk factors for homelessness and utilization of mental health services among 10,340 patients with serious mental illness in a large public mental health system. In: American Journal of Psychiatry. Band162, 2005, S.370–376, doi:10.1176/appi.ajp.162.2.370, PMID 15677603.
Kevin S. Douglas, Laura S. Guy, Stephen D. Hart:Psychosis as a risk factor for violence to others: A meta-analysis. In: Psychological Bulletin. Band135, Nr.5, 2009, ISSN1939-1455, S.679–706, doi:10.1037/a0016311 (apa.org[abgerufen am 23.Dezember 2018]).
J. S. Brekke, C. Prindle, S. W. Bae, J. D. Long:Risks for individuals with schizophrenia who are living in the community. Psychiatr Serv 52, 2001, S. 1358–1366. In: Psychiatric Service. Band52, 2001, S.1358–1366, doi:10.1176/appi.ajp.162.2.370, PMID 15677603.
Stavros Mentzos:Schöpferische Aspekte der psychotischen Symptomatik. Vergleichbare ästhetische Qualitäten im Traum und in der Psychose. In: Stavros Mentzos, Alois Münch (Hrsg.): Das Schöpferische in der Psychose (=Forum der psychoanalytischen Psychosentherapie. Band28). Vandenhoeck & Ruprecht, Göttingen 2012, ISBN 978-3-525-45236-3, S.13–26 (frankfurterpsychoseprojekt.de[PDF; 137kB; abgerufen am 23.April 2018]).
Mentzos (2012), S.13. Peter Hartwich vom Frankfurter Psychose-Projekt spezifizierte, „dass manche Symptome einen Schutzcharakter vor weiterer Fragmentierung der Psyche haben“ (Mentzos und Münch, 2012, S.9).
W. Gaebel, J. Zielasek: Focus on psychosis. In: Dialogues in clinical neuroscience. Band 17, Nummer 1, März 2015, S.9–18. PMID 25987859, PMC4421906(freier Volltext) (Review).
H. Müller, S. Laier, A. Bechdolf: Evidence-based psychotherapy for the prevention and treatment of first-episode psychosis. In: European archives of psychiatry and clinical neuroscience. Band 264, Supplement 1, November 2014, S.S17–S25. doi:10.1007/s00406-014-0538-0. PMID 25261211 (Review), PDF.
M. Bürgy: The concept of psychosis: historical and phenomenological aspects. In: Schizophrenia bulletin. Band 34, Nummer 6, November 2008, S.1200–1210, doi:10.1093/schbul/sbm136. PMID 18174608, PMC2632489(freier Volltext).
A. S. Khashan, K. M. Abel, R. McNamee, M. G. Pedersen, R. T. Webb, P. N. Baker, L. C. Kenny, P. B. Mortensen: Higher risk of offspring schizophrenia following antenatal maternal exposure to severe adverse life events. In: Archives of general psychiatry. Band 65, Nummer 2, Februar 2008, S.146–152, doi:10.1001/archgenpsychiatry.2007.20. PMID 18250252.
P. De Rossi, C. Chiapponi, G. Spalletta: Brain Functional Effects of Psychopharmacological Treatments in Schizophrenia: A Network-based Functional Perspective Beyond Neurotransmitter Systems. In: Current neuropharmacology. Band 13, Nummer 4, 2015, S.435–444. PMID 26412063, PMC4790396(freier Volltext) (Review).
J. E. Lisman, J. T. Coyle, R. W. Green, D. C. Javitt, F. M. Benes, S. Heckers, A. A. Grace: Circuit-based framework for understanding neurotransmitter and risk gene interactions in schizophrenia. In: Trends in neurosciences. Band 31, Nummer 5, Mai 2008, S.234–242. doi:10.1016/j.tins.2008.02.005. PMID 18395805, PMC2680493(freier Volltext) (Review).
Kristina M. Gicas; Puneet K. Parmar; Giulia F. Fabiano; Farzaneh Mashhadi:Substance-induced psychosis and cognitive functioning: A systematic review. In: Psychiatry Res. 308. Jahrgang, Februar 2022, S.114361, doi:10.1016/j.psychres.2021.114361, PMID 34979380 (englisch).
Michael Soyka:Psychopathological characteristics in alcohol hallucinosis and paranoid schizophrenia. In: Acta Psychiatrica Scandinavica. Band81, Nr.3, März 1990, S.255–9, doi:10.1111/j.1600-0447.1990.tb06491.x, PMID 2343749.
M. C. White, J. J. Silverman, J. W. Harbison:Psychosis associated with clonazepam therapy for blepharospasm. In: The Journal of Nervous and Mental Disease. Band170, Nr.2, Februar 1982, S.117–9, doi:10.1097/00005053-198202000-00010, PMID 7057171.
R. J. Hallberg, K. Lessler, F. J. Kane:Korsakoff-Like Psychosis Associated With Benzodiazepine Overdosage. In: The American Journal of Psychiatry. Band121, Nr.2, August 1964, S.188–9, doi:10.1176/ajp.121.2.188, PMID 14194223 (psychiatryonline.org).
D. W. Hedges, F. L. Woon, S. P. Hoopes:Caffeine-induced psychosis. In: CNS Spectrums. Band14, Nr.3, März 2009, S.127–9, PMID 19407709.
J. M. Cerimele, A. P. Stern, D. Jutras-Aswad:Psychosis following excessive ingestion of energy drinks in a patient with schizophrenia. In: The American Journal of Psychiatry. Band167, Nr.3, März 2010, S.353, doi:10.1176/appi.ajp.2009.09101456, PMID 20194494.
S. Glasner-Edwards, L. J. Mooney: Methamphetamine psychosis: epidemiology and management. In: CNS drugs. Band 28, Nummer 12, Dezember 2014, S.1115–1126, doi:10.1007/s40263-014-0209-8. PMID 25373627, PMC5027896(freier Volltext) (Review).
F. Rugani, S. Bacciardi, L. Rovai, M. Pacini, A. G. Maremmani, J. Deltito, L. Dell'osso, I. Maremmani: Symptomatological features of patients with and without Ecstasy use during their first psychotic episode. In: International journal of environmental research and public health. Band 9, Nummer 7, 07 2012, S.2283–2292, doi:10.3390/ijerph9072283. PMID 22851941, PMC3407902(freier Volltext).
A. M. Tomé, A. Filipe: Quinolones: review of psychiatric and neurological adverse reactions. In: Drug safety. Band 34, Nummer 6, Juni 2011, S.465–488, doi:10.2165/11587280-000000000-00000, PMID 21585220 (Review), PDF.
K. Michalak, A. Sobolewska-Włodarczyk, M. Włodarczyk, J. Sobolewska, P. Woźniak, B. Sobolewski: Treatment of the Fluoroquinolone-Associated Disability: The Pathobiochemical Implications. In: Oxidative medicine and cellular longevity. Band 2017, S.8023935, doi:10.1155/2017/8023935. PMID 29147464, PMC5632915(freier Volltext) (Review).
M. E. John, C. Thomas-Rozea, D. Hahn: Bath Salts Abuse Leading to New-Onset Psychosis and Potential for Violence. In: Clinical schizophrenia & related psychoses. Band 11, Nummer 2, Sommer 2017, S.120–124, doi:10.3371/CSRP.JORO.061314. PMID 24951715 (Review).
S. H. Gage, M. Hickman, S. Zammit: Association Between Cannabis and Psychosis: Epidemiologic Evidence. In: Biological psychiatry. Band 79, Nummer 7, April 2016, S.549–556, doi:10.1016/j.biopsych.2015.08.001, PMID 26386480 (Review) (freier Volltext).
S. D. Lichenstein, N. Manco u.a.: Systematic review of structural and functional neuroimaging studies of cannabis use in adolescence and emerging adulthood: evidence from 90 studies and 9441 participants. In: Neuropsychopharmacology. Band 47, Nummer 5, 04 2022, S.1000–1028, doi:10.1038/s41386-021-01226-9, PMID 34839363, PMC8938408(freier Volltext).
L. Prieto-Arenas, I. Díaz, M. C. Arenas: Gender Differences in Dual Diagnoses Associated with Cannabis Use: A Review. In: Brain sciences. Band 12, Nummer 3, März 2022, doi:10.3390/brainsci12030388, PMID 35326345, PMC8946108(freier Volltext) (Review).
G. Remington, G. Foussias, G. Fervaha, O. Agid, H. Takeuchi, J. Lee, M. Hahn: Treating Negative Symptoms in Schizophrenia: an Update. In: Current treatment options in psychiatry. Band 3, 2016, S.133–150, doi:10.1007/s40501-016-0075-8. PMID 27376016, PMC4908169(freier Volltext) (Review).
F. Bourque, E. van der Ven, A. Malla: A meta-analysis of the risk for psychotic disorders among first- and second-generation immigrants. In: Psychological medicine. Band 41, Nummer 5, Mai 2011, S.897–910, doi:10.1017/S0033291710001406. PMID 20663257 (Review), PDF.
U. Heilbronner, M. Samara, S. Leucht, P. Falkai, T. G. Schulze: The Longitudinal Course of Schizophrenia Across the Lifespan: Clinical, Cognitive, and Neurobiological Aspects. In: Harvard review of psychiatry. Band 24, Nummer 2, 2016 Mar-Apr, S.118–128, doi:10.1097/HRP.0000000000000092. PMID 26954596, PMC5079232(freier Volltext) (Review).
A. L. Gillespie, R. Samanaite, J. Mill, A. Egerton, J. H. MacCabe: Is treatment-resistant schizophrenia categorically distinct from treatment-responsive schizophrenia? a systematic review. In: BMC psychiatry. Band 17, Nummer 1, 01 2017, S.12, doi:10.1186/s12888-016-1177-y. PMID 28086761, PMC5237235(freier Volltext) (Review).
B. Adams, T. Sanders: Experiences of psychosis in borderline personality disorder: a qualitative analysis. In: Journal of mental health. Band 20, Nummer 4, August 2011, S.381–391, doi:10.3109/09638237.2011.577846. PMID 21770785 (Review).
S. Barnow, E. A. Arens, S. Sieswerda, R. Dinu-Biringer, C. Spitzer, S. Lang: Borderline personality disorder and psychosis: a review. In: Current psychiatry reports. Band 12, Nummer 3, Juni 2010, S.186–195, doi:10.1007/s11920-010-0107-9. PMID 20425279 (Review), PDF.
K. Schroeder, H. L. Fisher, I. Schäfer: Psychotic symptoms in patients with borderline personality disorder: prevalence and clinical management. In: Current opinion in psychiatry. Band 26, Nummer 1, Januar 2013, S.113–119, doi:10.1097/YCO.0b013e32835a2ae7. PMID 23168909 (Review).
D. P. Folsom, W. Hawthorne, L. Lindamer und andere:Prevalence and risk factors for homelessness and utilization of mental health services among 10,340 patients with serious mental illness in a large public mental health system. In: American Journal of Psychiatry. Band162, 2005, S.370–376, doi:10.1176/appi.ajp.162.2.370, PMID 15677603.
J. S. Brekke, C. Prindle, S. W. Bae, J. D. Long:Risks for individuals with schizophrenia who are living in the community. Psychiatr Serv 52, 2001, S. 1358–1366. In: Psychiatric Service. Band52, 2001, S.1358–1366, doi:10.1176/appi.ajp.162.2.370, PMID 15677603.
R. J. Hallberg, K. Lessler, F. J. Kane:Korsakoff-Like Psychosis Associated With Benzodiazepine Overdosage. In: The American Journal of Psychiatry. Band121, Nr.2, August 1964, S.188–9, doi:10.1176/ajp.121.2.188, PMID 14194223 (psychiatryonline.org).
H. Müller, S. Laier, A. Bechdolf: Evidence-based psychotherapy for the prevention and treatment of first-episode psychosis. In: European archives of psychiatry and clinical neuroscience. Band 264, Supplement 1, November 2014, S.S17–S25. doi:10.1007/s00406-014-0538-0. PMID 25261211 (Review), PDF.
A. M. Tomé, A. Filipe: Quinolones: review of psychiatric and neurological adverse reactions. In: Drug safety. Band 34, Nummer 6, Juni 2011, S.465–488, doi:10.2165/11587280-000000000-00000, PMID 21585220 (Review), PDF.
F. Bourque, E. van der Ven, A. Malla: A meta-analysis of the risk for psychotic disorders among first- and second-generation immigrants. In: Psychological medicine. Band 41, Nummer 5, Mai 2011, S.897–910, doi:10.1017/S0033291710001406. PMID 20663257 (Review), PDF.
S. Barnow, E. A. Arens, S. Sieswerda, R. Dinu-Biringer, C. Spitzer, S. Lang: Borderline personality disorder and psychosis: a review. In: Current psychiatry reports. Band 12, Nummer 3, Juni 2010, S.186–195, doi:10.1007/s11920-010-0107-9. PMID 20425279 (Review), PDF.
Epidemiology of suicide attempts among persons with psychotic disorder in the general population. In: Schizophrenia Research. Band124, Nr.1–3, 1.Dezember 2010, ISSN0920-9964, S.22–28, doi:10.1016/j.schres.2010.09.009 (sciencedirect.com[abgerufen am 23.Dezember 2018]).
Annika Clamor, Inga Frantz, Tania M. Lincoln:Psychotische Störungen und Schizophrenie. In: Klinische Psychologie & Psychotherapie. Springer Berlin Heidelberg, Berlin, Heidelberg 2020, ISBN 978-3-662-61813-4, S.947–1003, doi:10.1007/978-3-662-61814-1_44 (springer.com[abgerufen am 28.Juni 2024]).
Hendrik Müller, Andreas Bechdolf:Früherkennung und Frühbehandlung von Menschen mit erhöhtem Psychoserisiko. In: Handbuch Klinische Psychologie. Springer Berlin Heidelberg, Berlin, Heidelberg 2020, ISBN 978-3-662-45995-9, S.1–25, doi:10.1007/978-3-662-45995-9_26-1 (springer.com[abgerufen am 30.Juni 2024]).
Jan Conradi, Matthias Jäger, Stefan Kaiser:Update: Negativsymptome – Psychopathologie, Epidemiologie, Pathophysiologie und Behandlungsoptionen. Zürich Open Repository and Archive. 2013, doi:10.5167/uzh-91302 (uzh.ch[PDF]).
M. Lambert, P. Conus, D. I. Lubman, D. Wade, H. Yuen:The impact of substance use disorders on clinical outcome in 643 patients with first-episode psychosis. In: Acta Psychiatrica Scandinavica. Band112, Nr.2, 2005, ISSN1600-0447, S.141–148, doi:10.1111/j.1600-0447.2005.00554.x (wiley.com[abgerufen am 23.Dezember 2018]).
Epidemiology of suicide attempts among persons with psychotic disorder in the general population. In: Schizophrenia Research. Band124, Nr.1–3, 1.Dezember 2010, ISSN0920-9964, S.22–28, doi:10.1016/j.schres.2010.09.009 (sciencedirect.com[abgerufen am 23.Dezember 2018]).
M. Lambert, P. Conus, D. I. Lubman, D. Wade, H. Yuen:The impact of substance use disorders on clinical outcome in 643 patients with first-episode psychosis. In: Acta Psychiatrica Scandinavica. Band112, Nr.2, 2005, ISSN1600-0447, S.141–148, doi:10.1111/j.1600-0447.2005.00554.x (wiley.com[abgerufen am 23.Dezember 2018]).
Kevin S. Douglas, Laura S. Guy, Stephen D. Hart:Psychosis as a risk factor for violence to others: A meta-analysis. In: Psychological Bulletin. Band135, Nr.5, 2009, ISSN1939-1455, S.679–706, doi:10.1037/a0016311 (apa.org[abgerufen am 23.Dezember 2018]).